1. Home
  2. GLAD vs KROS Comparison

GLAD vs KROS Comparison

Compare GLAD & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLAD
  • KROS
  • Stock Information
  • Founded
  • GLAD 2001
  • KROS 2015
  • Country
  • GLAD United States
  • KROS United States
  • Employees
  • GLAD N/A
  • KROS N/A
  • Industry
  • GLAD Finance/Investors Services
  • KROS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GLAD Finance
  • KROS Health Care
  • Exchange
  • GLAD Nasdaq
  • KROS Nasdaq
  • Market Cap
  • GLAD 571.4M
  • KROS 558.9M
  • IPO Year
  • GLAD N/A
  • KROS 2020
  • Fundamental
  • Price
  • GLAD $28.51
  • KROS $14.53
  • Analyst Decision
  • GLAD Hold
  • KROS Buy
  • Analyst Count
  • GLAD 1
  • KROS 13
  • Target Price
  • GLAD $23.00
  • KROS $20.63
  • AVG Volume (30 Days)
  • GLAD 75.9K
  • KROS 487.4K
  • Earning Date
  • GLAD 08-04-2025
  • KROS 08-06-2025
  • Dividend Yield
  • GLAD 6.99%
  • KROS N/A
  • EPS Growth
  • GLAD 17.67
  • KROS N/A
  • EPS
  • GLAD 3.93
  • KROS 0.11
  • Revenue
  • GLAD $92,932,000.00
  • KROS $214,713,000.00
  • Revenue This Year
  • GLAD N/A
  • KROS $5,006.76
  • Revenue Next Year
  • GLAD $12.10
  • KROS N/A
  • P/E Ratio
  • GLAD $7.26
  • KROS $132.53
  • Revenue Growth
  • GLAD N/A
  • KROS 91657.70
  • 52 Week Low
  • GLAD $21.40
  • KROS $9.12
  • 52 Week High
  • GLAD $30.43
  • KROS $72.37
  • Technical
  • Relative Strength Index (RSI)
  • GLAD 75.48
  • KROS 64.67
  • Support Level
  • GLAD $27.75
  • KROS $13.26
  • Resistance Level
  • GLAD $27.33
  • KROS $14.68
  • Average True Range (ATR)
  • GLAD 0.47
  • KROS 0.41
  • MACD
  • GLAD 0.15
  • KROS 0.12
  • Stochastic Oscillator
  • GLAD 98.38
  • KROS 89.35

About GLAD Gladstone Capital Corporation

Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: